The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.


Letter to the editor

Editor, – The two recent articles on antiviral drugs were excellent - 'Antiviral drugs - mechanisms of action' by S. Locarnini (Aust Prescr 1993;16:78-81)and 'Antiviral drugs - clinical applications' by A.C. Street(Aust Prescr 1993;16:81-6). However, I felt that Dr Street's judgement that topical acyclovir (5% aqueous cream - which is unavailable in Australia) for orolabial and genital herpes simplex virus (HSV) infections had no clinical efficacy was a little harsh. I agree that it seems that the benefit of topical acyclovir for orolabial and recurrent genital HSV infections in immuno competent patients is limited to a reduction in viral shedding. However, topical acyclovir may have a role in primary genital herpes in immuno competent hosts. It reduces the duration of the lesions, but has minimal efficacy in reducing new vesicle formation.1,2

In immuno compromised patients with mucocutaneous HSV disease, topical therapy also results in a significant reduction in the period of pain and healing of lesions.3,4

Topical therapy may have an effective clinical application in the management of primary genital HSV infection, and minor mucocutaneous HSV infections in immuno compromised patients.5

Len Moaven
Virology Registrar
Westmead Hospital
Westmead, N.S.W.


Author's comments

Dr A. Street, the author of the article, comments:
There are two topical acyclovir preparations. The 3% acyclovir ointment isused for the treatment of herpetic conjunctivitis and keratitis. A 5% preparation, formulated as an ointment or aqueous cream, is available in the U.S.A. and Europe, but not in Australia.

Although topical5% acyclovir provides some clinical benefit for patients with primary genital herpes, oral acyclovir is significantly more effective and is the treatment of choice.6 Topical acyclovir is ineffective for recurrent genital herpes.7

Dr Moaven also notes that topical acyclovir has been reported to be effective in immuno compromised patients with limited mucocutaneous disease. However, since oral therapy is superior to topical therapy in immuno competent individuals, it seems unwise to rely on topical treatment for a group of patients in whom herpetic infections are generally more severe and frequent.

The available evidence shows that topical acyclovir is less effective than systemic therapy and thus has little clinical role at present, except for treatment of herpes simplex eye infections.


Len Moaven

Virology Registrar , ICPMR Westmead Hospital Westmead, N.S.W.

Dr A. Street